CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $198,680.04 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

CRISPR Therapeutics Stock Up 0.5 %

Shares of CRSP stock opened at $48.05 on Wednesday. The stock has a market cap of $4.08 billion, a P/E ratio of -17.67 and a beta of 1.68. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The business has a fifty day simple moving average of $47.11 and a 200-day simple moving average of $53.62.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the previous year, the business earned ($0.98) earnings per share. CRISPR Therapeutics’s quarterly revenue was down 99.3% on a year-over-year basis. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently modified their holdings of the company. Riggs Asset Managment Co. Inc. raised its position in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the last quarter. Global Trust Asset Management LLC grew its stake in CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC grew its position in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the period. NBC Securities Inc. increased its stake in CRISPR Therapeutics by 257.6% in the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRSP has been the topic of a number of research analyst reports. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Stifel Nicolaus lowered their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Chardan Capital reduced their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial lowered their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $75.19.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.